Navigation Links
Cynvenio Releases ClearID® Lung Cancer: a Highly-Targeted Genomic Blood Test for Lung and Thoracic Cancer Patients
Date:5/16/2017

Cynvenio Biosystems, Inc. a leader in personalized medicine technology and cancer diagnostics, has released its ClearID Lung Cancer blood test. Leveraging a highly-sensitive next-generation sequencing panel of 11 genes known to be altered in lung cancer, this new test is designed to quickly and accurately identify tumor-related genetic mutations that can be treated with targeted therapies.

ClearID Lung Cancer uses Cynvenio’s LiquidBiopsy® approach to identify circulating tumor DNA burden and detects somatic mutations as low as 0.13% with an accuracy of 99.76%, and a sensitivity of 95.9%. The test can be used at initial diagnosis to support treatment stratification and identification of targeted therapies. During treatment, it can be used to detect emergent genetic mutations associated with resistance to therapy and identify alternate therapeutic options.

The test results are available within 5-7 days and summarized in a report containing clinical interpretations of the identified biomarkers and variants, their association with drugs, related clinical trials, and experimental therapies to support treatment strategies.

“ClearID Lung Cancer provides physicians and their patients with a customized lung cancer panel that is focused on actionable mutations," said Dr. Paul Y. Song, Cynvenio’s Chief Medical Officer. "With a rapid turnaround time, the test enables quicker response times and more individualized and effective treatment.”

ClearID Lung Cancer can be used to complement conventional tissue biopsy. Requiring only a standard blood draw, ClearID is easier on the patient and can be repeated frequently to monitor changes in tumor status over time. ClearID is particularly useful when there is difficulty obtaining tissue biopsy material, or when it is not practical or advisable to do so for clinical reasons.

About Cynvenio Biosystems, Inc.

Cynvenio’s liquid biopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients.  Among the company’s breakthroughs is its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California. For more information, please visit http://www.cynvenio.comhttp://www.clearidmonitoring.com and http://www.liquidbiopsy.com.

LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.

Read the full story at http://www.prweb.com/releases/2017/05/prweb14339502.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Cynvenio and TME Research Announce Neoadjuvant Breast Cancer Monitoring Study (NEAT)
2. Cynvenio Releases Two New High Recovery LiquidBiopsy® CTC Capture Kits at 2017 AACR Annual Meeting in Washington, DC.
3. Cynvenio Biosystems Announces Expansion of Payer Network with Addition of Blue Cross Blue Shield of Illinois
4. Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test
5. Cynvenio and CollabRx Announce Partnership for Cancer Molecular Diagnostics
6. Cynvenio Biosystems Receives CLIA Certification for its Genomic Sequencing Laboratory
7. Cynvenio Biosystems to Present Clinical Data on Mutational Analysis of LiquidBiopsy® Tumor Samples at the 2013 ASCO Annual Meeting
8. METTLER TOLEDO Releases Conductivity Converter App
9. TOMA Biosciences Releases the COMPASS Tumor Profiling System
10. LabKey Releases Software Solution for Accelerating Large Molecule Development
11. AxioMed Releases Video Demonstrating Viscoelastic Properties of its Freedom Disc Replacement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... , ... May 17, 2017 , ... NDA Partners Chairman ... and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit ... his position at Eurofins and Cardinal Health, he was former Chief Operating Officer at ...
(Date:5/18/2017)... ... 2017 , ... Cognition Corporation ( http://www.cognition.us ), ... version 9.0 of the Cognition Cockpit platform. , “Our whole team has put ... CEO of Cognition. “We’re thrilled to finally be able to release it to ...
(Date:5/18/2017)... ... May 17, 2017 , ... HOLLOWAY AMERICA, a leading ... and dairy, munitions, and pharmaceutical/biotech, recently introduced The Revolution Lift™, a new precision-controlled ... improvement in technology comes on the heels of HOLLOWAY’s release of the intelliVessel™, ...
(Date:5/18/2017)... ... May 17, 2017 , ... Many complicated neurological ... to develop Alzheimer’s disease, while men are at greater risk for Parkinson’s disease. ... bias is the aim of a research program at Worcester Polytechnic Institute (WPI) ...
Breaking Biology Technology:
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/13/2017)... -- According to a new market research report "Consumer IAM ... and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global ... grow from USD 14.30 Billion in 2017 to USD 31.75 Billion by ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
Breaking Biology News(10 mins):